IP Library Granted Patent US 8,088,800
Granted Patent B2
US 8,088,800 · App. 10/598,281 · Granted Jan 3, 2012

4-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity

Assignee: Eli Lilly and Company
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,088,800
App. No.
10/598,281
Granted
Jan 3, 2012
Kind
B2
Abstract

The present invention relates to compounds of formulae (I) and (II) useful as opioid receptor antagonists for the treatment of obesity, wherein p is 0, 1, or 2; y is 0, 1, or 2; and z is 0, 1, or 2; X 1 is CH 2 , CH, or N; to form a indolinyl, indolyl, or benzimidazole ring respectively and including applicable double bonds and/or hydrogen atoms; X 2 is CH or N; R 1 to R 7 , R 3′ , p, y, and z are as defined in the claims.

Claims (23)

1. A compound selected from the group consisting of:

4-{5-[(3-Methyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide,

4-{5-[(2-Thiophen-2-yl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,

4-{5-[(3,3-Dimethyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide,

4-{5-[(2-Thiophen-2-yl-ethylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl}-benzamide,

4-{5-[(3-Methyl-butylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl}-benzamide,

4-{5-[(3,3-Dimethyl-butylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl}-benzamide,

4-(5-Hexylaminomethyl-indol-1-ylmethyl)-benzamide,

4-{5-[(3-Phenyl-propylamino)-methyl]-indol-1-ylmethyl}-benzamide,

4-(5-{[2-(2-Fluoro-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,

4-{5-[(2-Hydroxy-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,

4-(5-{[2-(4-Methoxy-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,

4-{5-[(2-Chloro-6-fluoro-benzylamino)-methyl]-indol-1-ylmethyl}-benzamide,

4-{5-[(2-Pyridin-3-yl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,

4-(5-{[2-(2-Ethoxy-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,

4-(5-{[2-(Tetrahydro-pyran-4-yl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,

4-{5-[(2-Cyclohex-1-enyl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,

4-(5-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,

4-{5-[(2-Ethyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide,

1-{4-[(3-Methyl-butylamino)-methyl]-benzyl}-2,3-dihydro-1H-indole-5-carboxylic acid amide,

1-{4-[(3-Methyl-butylamino)-methyl]-benzyl}-1H-indole-5-carboxylic acid amide,

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in association with a carrier, diluent and/or excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2006
From: BENESH, DANA RAE; BLANCO-PILLADO, MARIA-JESUS
To: ELI LILLY AND COMPANY
Reel/Frame 018211/0603 →
Continuity (2)
Provisional Application 60553176 · Mar 15, 2004
Related Publication 20070155793A1 · Jul 5, 2007